Vanguard Personalized Indexing Management LLC Acquires 6,310 Shares of Danaher Corporation $DHR

Vanguard Personalized Indexing Management LLC increased its position in Danaher Corporation (NYSE:DHR) by 9.0% during the 4th quarter, Holdings Channel reports. The firm owned 76,247 shares of the conglomerate’s stock after acquiring an additional 6,310 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Danaher were worth $17,454,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp grew its stake in Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock worth $6,345,529,000 after purchasing an additional 472,608 shares in the last quarter. Capital International Investors grew its stake in Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares in the last quarter. Norges Bank bought a new position in Danaher in the fourth quarter worth approximately $2,177,106,000. Generation Investment Management LLP grew its stake in Danaher by 14.1% in the fourth quarter. Generation Investment Management LLP now owns 7,589,661 shares of the conglomerate’s stock worth $1,737,425,000 after purchasing an additional 934,995 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in Danaher by 14.9% in the fourth quarter. Franklin Resources Inc. now owns 4,931,303 shares of the conglomerate’s stock worth $1,128,874,000 after purchasing an additional 637,666 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $179.95 on Monday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. The company has a market capitalization of $127.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 2.30 and a beta of 0.81. The business’s 50-day moving average is $180.93 and its two-hundred day moving average is $204.62.

Danaher (NYSE:DHR) last posted its earnings results on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The company’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the firm earned $1.88 EPS. Research analysts predict that Danaher Corporation will post 8.45 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio (DPR) is 30.95%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Analysts Set New Price Targets

A number of research firms have weighed in on DHR. Royal Bank Of Canada began coverage on Danaher in a report on Thursday, May 14th. They set an “outperform” rating and a $200.00 target price for the company. Piper Sandler started coverage on Danaher in a report on Thursday. They set a “neutral” rating and a $200.00 price objective for the company. The Goldman Sachs Group decreased their price objective on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a report on Monday, April 13th. Wolfe Research lowered Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Finally, HSBC decreased their price objective on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $233.61.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.